ArticleSurgical endoscopy2026
Cohort profile: the National Early Gastrointestinal Cancer Cohort (NEGCC) study in China.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundGastrointestinal cancers represent a significant public health burden in China. Current evidence regarding treatment approaches for early-stage gastrointestinal malignancies predominantly derives from case reports and small-scale studies. Furthermore, existing gastrointestinal disease cohorts primarily focus on community-based screening or high-risk populations, leaving a substantial gap in systematically collected data from hospitalized early stage cancer patients.
methodsWe established the National Early Gastrointestinal Cancer Cohort (NEGCC), which constitutes, to our knowledge, one of the most comprehensive multicenter cohorts of hospitalized early gastrointestinal cancer patients in China and Asia. This initiative has been complemented by the development of a dedicated clinical platform, an integrated database, a biorepository, and a health economic evaluation framework. The study enrolled patients who underwent surgical resection for early gastrointestinal cancer at participating institutions between January 1, 2015, and June 30, 2023, with planned follow-up continuing until December 31, 2026. Standardized data collection includes comprehensive baseline characteristics, treatment parameters, and prospective outcome measures, integrated through a centralized electronic registry ( https://bjdigest.sino-med.net ).
resultsThe initial dataset comprises 3,348 patients who underwent surgical management at the PLA General Hospital between January 2015 and December 2019. The cohort had a male predominance (73.7%), with a mean age of 60.9 ± 10.3 years (range: 19-93). Most participants were married (98.7%), and 31.8% had medical insurance coverage.
conclusionThe NEGCC initiative provides a robust platform for generating high-quality evidence on early gastrointestinal cancer management. This resource will facilitate the development of improved diagnostic and therapeutic strategies, inform clinical practice guidelines, and enable the identification of disease-specific biomarkers. Additionally, the cohort will support rigorous health economic analyses to identify cost-effective treatment approaches, ultimately aiming to improve outcomes for patients with early gastrointestinal cancer.
Indexed as
Identifiers
41408438What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.